Abstracts tagged "Lupus nephritis"

Abstract Number: 0769 • ACR Convergence 2021
Renal Outcomes in 1528 Childhood-onset Systemic Lupus Erythematosus Patients: A Brazilian Multicenter Study
Ana Paula Sakamoto¹, Clovis Silva², Aline Islabão³, Glaucia Novak², Beatriz Molinari², Rosa Pereira⁴, Claudia Saad-Magalhães⁵, Gleice Clemente⁶, Daniela Petry Pioto⁷, Nadia Aikawa⁴, Ana Pita², Vitor Trindade², Simone Appenzeller⁸, Luciana Carvalho⁹, Carlos Rabelo-Junior¹⁰, Adriana Fonseca¹¹, Flavio Sztajnbok¹², Maria Santos¹³, Blanca Elena Rios Gomes Bica¹⁴, Evaldo Sena¹⁵, Ana Moraes¹⁶, Melissa Fraga⁶, Teresa Robazzi¹⁷, Paulo Spelling¹⁸, Iloite Scheibel¹⁹, Andre Cavalcanti²⁰, Erica Matos²¹, Luciano Guimarães²², Flavia Santos²³, Licia Maria Henrique Mota²⁴, Eloisa Bonfá⁴ and Maria Terreri²⁵, ¹Federal University of So Paulo (UNIFESP), São Paulo, Brazil, ²Pediatric Rheumatology Unit, Children’s Institute, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ³Pediatric Rheumatology Unit, Hospital da Criança de Brasília Jose Alencar, Brasilia, DF, Brazil, ⁴Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁵Pediatric Rheumatology Division, São Paulo State University (UNESP) – Faculdade de Medicina de Botucatu, Botucatu, Botucatu, Brazil, ⁶Universidade Federal de São Paulo, São Paulo, Brazil, ⁷Pediatric Rheumatology Unit, Universidade Federal de São Paulo, São Paulo, SP, Brazil, ⁸Hospital das Clínicas da Universidade Estadual de Campinas, Campinas, Brazil, ⁹Pediatric Rheumatology Unit, Ribeirão Preto Medical School – University of São Paulo, Ribeirão Preto, SP, Brazil, ¹⁰Pediatric Rheumatology Unit, Hospital Geral de Fortaleza, Fortaleza, CE, Brazil, ¹¹Pediatric Rheumatology Unit, Rio de Janeiro Federal University (IPPMG-UFRJ), Rio de Janeiro, RJ, Brazil, ¹²UFRJ/UERJ, Rio de Janeiro, Brazil, ¹³Pediatric Rheumatology Unit, Irmandade da Santa Casa de Misericórdia de São Paulo, São Paulo, SP, Brazil, ¹⁴Faculdade de Medicina, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil, ¹⁵Pediatric Rheumatology Unit, Lauro Vanderley University Hospital, João Pessoa, PB, Brazil, ¹⁶Pediatric Rheumatology Unit, Federal University of Pará, Belém, PA, Brazil, ¹⁷Pediatric Rheumatology Unit, Federal University of Bahia, Salvador, BA, Brazil, ¹⁸Pediatric Rheumatology Unit, Hospital Evangélico de Curitiba, Curitiba, PR, Brazil, ¹⁹Pediatric Rheumatology Unit, Hospital Criança Conceição, Porto Alegre, RS, Brazil, ²⁰Pediatric Rheumatology Unit, Federal University of Pernambuco, Recife, PE, Brazil, ²¹Pediatric Rheumatology Unit, Federal University of Mato Grosso do Sul, Campo Grande, MS, Brazil, ²²Pediatric Rheumatology Unit, University of Brasília, Brasilia, DF, Brazil, ²³Pediatric Rheumatology Unit, Federal University of Minas Gerais, Belo Horizonte, Belo Horizonte, MG, Brazil, ²⁴Universidade de Brasília, Brasilia, Brazil, ²⁵UNIFESP, São Paulo, Brazil
Background/Purpose: Lupus nephritis is a frequent manifestation in childhood-onset systemic lupus erythematosus (cSLE) and has a great potential for chronic kidney disease (CKD), requiring dialysis…
Abstract Number: 1460 • ACR Convergence 2021
Lupus Nephritis Renal Responses in Relation to Treatment and Demographics: Observations from a Multi-racial/ethnic Cohort of 159 Patients in the NYU Lupus Registry
Mayce Haj-Ali¹, Kristina Deonaraine², Alexis Engel³, Yingzhi Qian¹, Amit Saxena⁴, Peter Izmirly², Jill Buyon⁴ and H. Michael Belmont⁴, ¹NYU Grossman School of Medicine, New York, NY, ²New York University School of Medicine, New York, NY, ³NYU Langone Health, New Yok, NY, ⁴NYU School of Medicine, New York, NY
Background/Purpose: Lupus nephritis (LN) disproportionately affects racial and ethnic populations. Contreras reported African-American (AA) and Hispanic patients had worse outcomes as compared to patients of…
Abstract Number: 1754 • ACR Convergence 2021
Effect of Belimumab on Autoantibodies, Complement, and B-Cell Subsets in Patients with Lupus Nephritis
Brad Rovin¹, Richard Furie², Ana Malvar³, Cynthia Aranow⁴, Jose M Pego-Reigosa⁵, Elena Zakharova⁶, Andreas Schwarting⁷, Angela Jones-Leone⁸, Anuradha Madan⁸, Jennifer Gilbride⁹, David Roth⁸, Yulia Green⁹ and André van Maurik¹⁰, ¹Ohio State University Wexner Medical Center, Columbus, OH, ²Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ³Hospital Fernandez, Buenos Aires, Argentina, ⁴Feinstein Institutes for Medical Research, Manhasset, NY, ⁵Complexo Hospitalario Universitario de Vigo, Hospital Meixoeiro, Galicia Sur Health Research Institute, Rheumatology Department and IRIDIS (Investigation in Rheumatology and Immune-Mediated Diseases) Group, Vigo, Spain, ⁶Moscow City Clinical Hospital n.a. S.P. Botkin, Moscow, Russia, ⁷University Center of Autoimmunity, Mainz, Germany, ⁸GlaxoSmithKline, Collegeville, PA, ⁹GlaxoSmithKline, Brentford, United Kingdom, ¹⁰GlaxoSmithKline, Stevenage, Hertfordshire, United Kingdom
Background/Purpose: Lupus nephritis (LN) is a complication affecting ~40% of patients with systemic lupus erythematosus (SLE). Belimumab (BEL), an anti–B-lymphocyte stimulator therapy, was approved in…
Abstract Number: 0326 • ACR Convergence 2021
Apolipoprotein L1 (APOL1) in African-American SLE: Frequency and Clinical Associations
Michelle Petri¹, Romy Kallas², Jessica Li³, Laurence Magder⁴ and Daniel Goldman¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Lankenau Medical Center, Lankenau, PA, ³Johns Hopkins University, Baltimore, MD, ⁴University of Maryland, Baltimore, Baltimore, MD
Background/Purpose: The APOL1 gene is implicated in induction of TLR3 agonists and interferons as well as in autophagy. Two genetic variants, G1 (2 single nucleotide…
Abstract Number: 0784 • ACR Convergence 2021
Use of EuroLupus Cyclophosphamide Dosing for the Treatment of Lupus Nephritis in Childhood-Onset Systemic Lupus Erythematosus in North America
Laura Cannon¹, Scott Wenderfer², Laura Lewandowski³, Jennifer Cooper⁴, Beatrice Goilav⁵, Andrea Knight⁶, Aimee Hersh⁷, Stacy Ardoin⁸ and Rebecca Sadun¹, ¹Duke University, Durham, NC, ²Baylor College of Medicine, Houston, TX, ³NIAMS, NIH, Rockville, MD, ⁴University of Colorado/Children's Hospital Colorado, Denver, CO, ⁵Children's Hospital at Montefiore, Bronx, NY, ⁶Hospital for Sick Children, Toronto, ON, Canada, ⁷University of Utah, Salt Lake City, UT, ⁸Nationwide Children's Hospital, Columbus, OH
Background/Purpose: Childhood-onset systemic lupus erythematosus (cSLE) has higher rates of lupus nephritis (LN) than adult-onset SLE, often requiring intensive immunosuppression. This study examined North American…
Abstract Number: 1461 • ACR Convergence 2021
Belimumab Improves Renal Responses in Patients with or Without Steroid Pulses During Induction Therapy for Lupus Nephritis
Richard Furie¹, Frédéric Houssiau², Liz Lightstone³, Xueqing Yu⁴, Julia Weinmann-Menke⁵, Yoshiya Tanaka⁶, Angela Jones-Leone⁷, Tania Gonzalez-Rivera⁷, Jennifer Gilbride⁸, Anuradha Madan⁷, Yulia Green⁸ and David Roth⁷, ¹Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ²Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium, ³Department of Immunology and Inflammation, Imperial College, London, United Kingdom, ⁴Guangdong Provincial People’s Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China (People's Republic), ⁵University Hospital Mainz, Mainz, Germany, ⁶University of Occupational and Environmental Health, Kitakyushu, Japan, ⁷GlaxoSmithKline, Collegeville, PA, ⁸GlaxoSmithKline, Brentford, United Kingdom
Background/Purpose: In the BLISS-LN trial (GSK Study BEL114054; NCT01639339), the administration of belimumab (BEL), a B-lymphocyte stimulator antagonist, resulted in improved renal outcomes in patients…
Abstract Number: 1756 • ACR Convergence 2021
Class V Systemic Lupus Erythematosus Nephritis Patients Are Undertreated and Face Similar Adverse Renal Outcomes as Class III/IV Patients
April Barnado and Alex Camai, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Few studies have investigated treatment patterns and renal outcomes in class V systemic lupus erythematosus (SLE) nephritis patients compared to class III/IV patients. Prior…
Abstract Number: 0328 • ACR Convergence 2021
Natural Language Processing to Identify Lupus Nephritis Phenotype in Electronic Health Records
Yu Deng¹, Jennifer Pacheco¹, Anh Chung¹, Chengsheng Mao¹, Joshua Smith², juan zhao¹, Wei-Qi Wei², April Barnado³, Chunhua Weng⁴, Cong Liu⁴, Adam Gordon¹, Jingzhi Yu¹, Yacob Tedla¹, Abel Kho¹, Rosalind Ramsey-Goldman¹, Theresa Walunas¹ and Yuan Luo¹, ¹Northwestern University, Chicago, IL, ²Vanderbilt Universty Medical Center, Nashville, TN, ³Vanderbilt University Medical Center, Nashville, TN, ⁴Columbia University, New York, NY
Background/Purpose: Lupus nephritis (LN) is a major disease manifestation of Systemic lupus erythematosus (SLE) leading to organ damage and increased mortality. Accurately identifying lupus nephritis…
Abstract Number: 0874 • ACR Convergence 2021
Serum Galectin-9 and CXCL-10 but Not Their Urinary Levels Reflect Lupus Activity
Pankti Mehta, Pratibha Singh and Amita Aggarwal, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: SLE is characterized by increased type I IFN signature in the blood and immune cells. Traditionally, type I IFN signature is measured by gene…
Abstract Number: 1482 • ACR Convergence 2021
LN Urinary Proteomics Reveals Common Biological Pathways Identified by Distinct Disease Measures
Paul Newcombe¹, Madhu Ramaswamy², Dominic Sinibaldi², Catharina Lindholm³, Frederick Jones¹, Ahmad Akhgar², Philip Brohawn², Raj Tummala² and Wendy White², ¹BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ²BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ³BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
Background/Purpose: LN is a severe consequence of SLE and there is a huge unmet need for discovery of urine protein biomarkers that provide non-invasive surrogates…
Abstract Number: 1766 • ACR Convergence 2021
Itolizumab-induced Modulation of Cell Surface CD6 Is a Pharmacodynamic Marker of Drug Activity in SLE Patients
Dalena Chu¹, Leslie Chinn², Jeanette Ampudia¹, Krishna Polu¹, Joel Rothman¹, Maple Fung³, Dolca Thomas⁴, Chaim Putterman⁵, Cherie Ng¹ and Stephen Connelly¹, ¹Equillium, Inc., La Jolla, CA, ²Equillium, Inc., South San Francisco, CA, ³Equillium, Inc., San Diego, CA, ⁴Equillium, Inc., Brooklyn, NY, ⁵Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Itolizumab (ITO) is a novel first-in-class monoclonal antibody (IgG1-k) specific for CD6, a co-stimulatory receptor that is highly expressed on T cells that plays…
Abstract Number: 0340 • ACR Convergence 2021
Urinary L-selectin Predicts Disease Activity and Histological Changes in Lupus Nephritis
Huihua Ding¹, Yiwei Shen¹, Min Dai¹, Chandra Mohan² and Nan Shen³, ¹Shanghai JiaoTong University School of Medicine, Shanghai, China (People's Republic), ²University of Houston, Houston, TX, ³Shanghai Jiang Tong University School of Medicine, Shanghai, China (People's Republic)
Background/Purpose: There remains unmet needs of non-invasive markers of disease activity, damage, prognosis, and treatment response in lupus nephritis patients. Here, we aim to validate…
Abstract Number: 0888 • ACR Convergence 2021
Disease Flares in Lupus Are Concordant with Ruminococcus Blautia Gnavus Blooms Within Unstable Gut Microbiota Communities
Doua Azzouz¹, Ze Chen¹, Zhi Li¹, Jing Deng¹, Peter Izmirly¹, David Fenyo¹, Jill Buyon¹, Alexander Alekseyenko² and Gregg Silverman¹, ¹NYU Grossman School of Medicine, New York, NY, ²Medical University of South Carolina, Charleston, SC
Background/Purpose: Systemic Lupus Erythematosus is the archetypic systemic autoimmune disease in which dysbiosis in the gut microbiome has been postulated to contribute to disease development…
Abstract Number: 1484 • ACR Convergence 2021
B Cell Intracellular IFNβ as a Unique Cellular Marker for the Development of Lupus Nephritis
Fatima Alduraibi¹, Huma Fatima¹, Winn Chatham², Hui-Chen Hsu¹ and John Mountz¹, ¹University of Alabama Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Our laboratory previously demonstrated a strong association of B cell intracellular interferon beta (IFNβ) with the development of anti-Smith/ribonuclear protein (Sm/RNP), anti-DNA, and lupus…
Abstract Number: 1936 • ACR Convergence 2021
A Neutrophil Degranulation Signature Identifies Proliferative Lupus Nephritis
Andrea Fava¹, Jessica Li¹, Daniel Goldman², Brendan Antiochos¹, Jose Monroy-Trujillo¹, Derek Fine¹, Mohamed G. Atta¹, Jill Buyon³, Joel Guthridge⁴, Judith James⁴, Michelle Petri² and Accelerating Medicines Partership (AMP) RA/SLE Network⁵, ¹Johns Hopkins University, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³NYU School of Medicine, New York, NY, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Brigham and Women's Hospital, Everett, MA
Background/Purpose: The identification of intrarenal pathological processes is key to develop better diagnostic and treatment strategies in lupus nephritis (LN). But the direct comprehensive study…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].